Roche mtm laboratories AG; Bringing the Power of p16 to the prevention of cervical cancer

Worldwide, cervical cancer is the second most common cancer in women, with over 400,000 cases per year. Identifying High-grade disease early, the immediate pre-cursor to cancer, is a critical component to a good prognosis.

mtm’s patent protected CINtec® products are adjunctive tools for histology and cytology, applications that enable the early and accurate detection of cervical disease. CINtec® products are based on detecting the over-expression of the cellular protein p16INK4a (p16), a biomarker correlated with the oncogenic transformation of cervical cells’ response to persistent infection with High Risk Human Papilloma Virus (HR-HPV). Identifying the over-expression of p16 offers the potential for highly specific and accurate diagnosis of even symptomless early stages of cervical disease.

We welcome you to learn more about our products and our company. Please select your territory.